Adaptam Therapeutics has secured $3,000,000 in investment capital, the company announced today. This funding round marks a significant step for the biotechnology firm focused on developing novel cancer treatments. The capital infusion will enable Adaptam to further advance its pipeline of next-generation immunotherapies aimed at critical challenges in oncology.
The company specializes in pioneering next-generation cancer immunotherapies by disrupting the immunosuppressive myeloid tumor microenvironment (TME) through glyco-immune checkpoints. Adaptam's research addresses the resistance to existing treatments driven by immunosuppressive myeloid cells, such as tumor-associated macrophages (TAMs), which are prevalent in solid tumors. Their discoveries in cancer immunology, T cell, and myeloid cell biology have identified specific glycan interactions with immune cells as key drivers of myeloid-mediated immune suppression.
With this new funding, Adaptam Therapeutics plans to accelerate the development of its first-in-class, antibody-based therapies. These therapies are designed to target the central glycobiology pathways involved in myeloid immunosuppression. The company leverages its in-house antibody discovery expertise to develop innovative antibody-drug conjugates (ADCs) and bispecific antibodies aimed at reprogramming the immunosuppressive TME and boosting T cell activity in solid tumors.
This investment will support Adaptam's ongoing research and development efforts, advancing its programs closer to clinical application. As a spin-off from CIC bioGUNE, Adaptam has previously received support from founding investor Criteria Bio Ventures and competitive national and European funding, including several prestigious European Research Council (ERC) grants. The company remains committed to transforming cancer treatment across multiple indications by focusing on its unique approach to the tumor microenvironment.
